COMMUNIQUÉS West-GlobeNewswire

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
28/04/2026
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
TOMI Environmental Solutions to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today, April 28, 2026, at 1 p.m. ET
28/04/2026
Livestream to Highlight TOMI’s Innovation Acceleration Business Model and Global Decontamination Growth Strategy FREDERICK, Md., April 28, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: [...]
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
28/04/2026
New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), [...]
Ritedose Reaches “1,000 Hours of Purpose”
28/04/2026
Employee-led initiative deepens Ritedose's commitment to Midlands nonprofits and the communities they serve COLUMBIA, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation today announced a significant [...]
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
28/04/2026
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program Grand Cayman, Cayman Islands, April 28, 2026 ( [...]
Dr. Petros Kotsidis: KFSH Positions AI as a Scalable Model for Real-World Healthcare Innovation
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Dr. Petros Kotsidis, Chief Digital Officer at King Faisal Specialist Hospital & Research Centre (KFSH), said the hospital is adopting a system-level approach to [...]
KFSH Awards Innovation Challenge Winners at C3 Davos of Healthcare™ Silicon Valley Summit
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH), a Global Strategic Partner at the C3 Davos of Healthcare™ Silicon Valley Summit, awarded the winners of [...]
Dr. Björn Zoëga: Scaling Integrated Digital Systems Will Define the Future of Healthcare
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Dr. Björn Zoëga, CEO of King Faisal Specialist Hospital & Research Centre Riyadh (KFSH), said the future of healthcare will be defined not by innovation itself, [...]
Yinuo Chen, founder of three major Fertility centers—Tulip, ONELIFE, and Sino—was invited to participate in the Shanghai Medical Exhibition
28/04/2026
BISHKEK, Kyrgyzstan, April 28, 2026 (GLOBE NEWSWIRE) -- Yinuo Chen, founder of three major fertility centers—Kyrgyzstan Tulip, Thailand ONELIFE, and Georgia Sino—was invited to participate in the 2026 Shanghai [...]
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
28/04/2026
OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1/2a multi-centre, multi- [...]
Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
28/04/2026
DEESIDE, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today [...]
Transactions in connection with share buy-back program
28/04/2026
Company announcement no. 12 - 26 28 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Clariane annonce l’offre de 230 millions d’euros d’obligations senior additionnelles en vue de refinancer ses obligations hybrides vertes perpetuelles
28/04/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Holivita Launches a New Platform, Offering a Human-Centric Blueprint for Health Through AI and Your DNA
28/04/2026
DUBAI, United Arab Emirates, April 28, 2026 (GLOBE NEWSWIRE) -- Holivita , a forward-thinking med-tech company, announces the launch of its platform designed to support everyday health and self-care. “Health should no [...]
Clariane has launched a proposed offering of €230 million of additional senior notes to refinance its hybrid green perpetual bonds
28/04/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
28/04/2026
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall [...]
Castle Rock Hormone Health Announces National Franchise Launch with Franchise Sidekick Amid Growing Demand for Longevity Medicine
28/04/2026
Castle Rock Hormone Health launches a national franchise program with Franchise Sidekick, targeting 100–250 new clinics in 2026 to meet rising demand for longevity-focused, cash-pay hormone and preventive health [...]
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
28/04/2026
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in [...]
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
28/04/2026
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist 1 The trial met both weight loss primary [...]

Pages